Coya Therapeutics Inc. Common Stock (COYA)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with what is knowable. Coya is a clinical-stage biotech with eight employees, developing Treg therapies. It has no approved product and no durable moat I can identify; its value rests on clinical trial outcomes, not repeat customers or pricing power. In fiscal FY2025, the year ended 2025-12-31, it reported revenue of $7.9M and a net loss of $21.2M, or diluted EPS of -$1.27. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $243,745 and net loss was $6.6M, or diluted EPS of -$0.28. That net loss was many times revenue. Trailing free cash flow was -$16.6M, a -15.8% FCF yield on the $105M market cap at the 2026-10-13 close. FairStock's calculations show P/E of -4.18, P/B of 2.43, ROE of -60.54%, ROCE of -32.27%, Piotroski F-Score of 1/9, and an Altman Z-Score of 14.00. The Lynch category is none, because it has lost money in each of the last four years. Altman's high score may reflect low liabilities, but it does not create earning power. Growth is erratic: fiscal FY2024, ended 2024-12-31, revenue was $3.6M; fiscal FY2025 revenue was $7.9M; then fiscal Q1 2026, ended 2026-03-31, revenue was $251,147, and fiscal Q2 2026 was $243,745, with continuing losses. At $4.47, the market is paying for hope, not proven value. I would want clinical validation and a clearer cash runway before calling this a business rather than a speculation.

In plain English: Coya Therapeutics is a tiny clinical-stage biotech with eight employees, developing therapies that aim to improve regulatory T cells; it has no approved product and is not profitable. Sales are minimal — revenue was $243,745 in fiscal Q2 2026, the quarter ended 2026-06-30 — while it lost $6.6 million. At $4.47 on 2026-10-13, the shares look expensive against current sales and cash losses, and the business depends on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer